Survival Lower for Children With Leukemia Living on Texas-Mexico Border
TUESDAY, Feb. 21, 2023 -- For children with acute lymphoblastic leukemia (ALL), but not those with acute myeloid leukemia (AML), living along the Texas-Mexico border is associated with inferior survival, according to a study published online Feb. 21... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 21, 2023 Category: Pharmaceuticals Source Type: news
Allogeneic Stem Cell Transplant Feasible for Leukemia in Elderly Patients
TUESDAY, Feb. 21, 2023 -- In elderly adults aged 60 years and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), allogeneic hematopoietic stem cell transplant (HSCT) can be performed with acceptable overall survival and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 21, 2023 Category: Pharmaceuticals Source Type: news
Devastation as ‘extremely loved' three-year-old dies after battle with cancer
Porsha was diagnosed with acute myeloid leukaemia in September 2021 and has spent every day at the hospital since. (Source: Daily Express - Health)
Source: Daily Express - Health - February 4, 2023 Category: Consumer Health News Source Type: news
Inflammation Linked to Inferior Outcomes in Leukemia
WEDNESDAY, Jan. 18, 2023 -- A unique inflammation signature, in which atypical B cells are identified, is associated with worse outcomes in patients with acute myeloid leukemia (AML), according to a study published online Jan. 11 in Nature... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 18, 2023 Category: Pharmaceuticals Source Type: news
Blood Test 24 Hours After Starting Chemo Predicts AML Survival Blood Test 24 Hours After Starting Chemo Predicts AML Survival
Protein changes in peripheral blood samples in the first 24 hours after starting chemotherapy could predict which patients with acute myeloid leukemia respond.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 18, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Patient - Centered Communication Tool Feasible for Seniors With Acute Myeloid Leukemia
Patients, caregivers scored higher on AML knowledge and perceived greater efficacy in communicating with oncologists (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 22, 2022 Category: Cancer & Oncology Tags: Oncology, Geriatrics, Journal, Source Type: news
Patient-Centered Communication Tool Feasible for Seniors With Acute Myeloid Leukemia
THURSDAY, Dec. 22, 2022 -- Incorporation of an innovative patient-centered communication tool (UR-GOAL tool) is feasible for older adults with newly diagnosed acute myeloid leukemia (AML), according to study published online Dec. 19 in Cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 22, 2022 Category: Pharmaceuticals Source Type: news
Mayo Clinic Q & amp;A podcast: Advancing treatments for acute myeloid leukemia
Acute myeloid leukemia (AML), also called acute myelogenous leukemia, is a cancer of the blood and bone marrow, the spongy tissue inside bones where blood cells are made. The disease progresses rapidly, affecting a group of white blood cells called myeloid cells, which normally develop into mature red blood cells, white blood cells and platelets. "There are acute and chronic leukemias, explains Dr. James Foran, an oncologist at Mayo Clinic. "The chronic ones tend to happen… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 20, 2022 Category: Databases & Libraries Source Type: news
REZLIDHIA (olutasidenib), FDA-Approved for Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia, Available at Biologics by McKesson
CARY, N.C., Dec. 19, 2022 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Rigel Pharmaceuticals as one of two specialty pharmacies in a limited distribution network for REZLIDHIATM (olutasidenib), which is indicated for... (Source: McKesson News)
Source: McKesson News - December 19, 2022 Category: Information Technology Source Type: news
' Astonishing' Results: Skip Salvage Chemo, Go Straight to HSCT'Astonishing' Results: Skip Salvage Chemo, Go Straight to HSCT
Investigators said they were astonished by the results they saw when patients with refractory acute myeloid leukemia went straight to an allogeneic stem cell transplant.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 11, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Worldwide Efforts Needed to Close Regional HSCT Utilization Gap Worldwide Efforts Needed to Close Regional HSCT Utilization Gap
Although hematopoietic stem cell transplants (HSCT) offer a cure for acute myeloid leukemia, in some countries only 5% of patients are offered this option.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 10, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
FDA Approves Olutasidenib (Rezlidhia) for Certain Patients With AML FDA Approves Olutasidenib (Rezlidhia) for Certain Patients With AML
The drug has been approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 2, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Rezlidhia (olutasidenib) for Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
December 1, 2022 -- On December 1, 2022, the Food and Drug Administration (FDA) approved olutasidenib (Rezlidhia) capsules for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 1, 2022 Category: Drugs & Pharmacology Source Type: news
“ Why Aren ’ t We All Bacteria? ” Siddhartha Mukherjee Explores the Power of Cells
It’s hard to miss what appears to be dry cleaning hanging on the wall of Siddhartha Mukherjee’s apartment in New York City’s Chelsea neighborhood. The apartment is a sunny, stylish, open space, filled with modern furniture, decorated with sculpture and paintings—and then, in perhaps the most conspicuous spot on the living room, is a brown felt suit with very long pants, draped over a plain wooden hanger. It looks entirely out of place—but it’s not.
The suit is the handiwork of German artist Joseph Bueys, who created the improbable bit of fabric art as a tribute to the nomadic Tatars who,...
Source: TIME: Science - October 31, 2022 Category: Science Authors: Jeffrey Kluger Tags: Uncategorized Magazine Science Source Type: news
‘ Why Aren ’ t We All Bacteria? ’ Siddhartha Mukherjee Explores the Power of Cells
It’s hard to miss what appears to be dry cleaning hanging on the wall of Siddhartha Mukherjee’s apartment in New York City’s Chelsea neighborhood. The apartment is a sunny, stylish, open space, filled with modern furniture, decorated with sculpture and paintings—and then, in perhaps the most conspicuous spot on the living room, is a brown felt suit with very long pants, draped over a plain wooden hanger. It looks entirely out of place—but it’s not.
The suit is the handiwork of German artist Joseph Bueys, who created the improbable bit of fabric art as a tribute to the nomadic Tatars who,...
Source: TIME: Science - October 31, 2022 Category: Science Authors: Jeffrey Kluger Tags: Uncategorized Magazine Science Source Type: news
